Reva Schneider
Medical Oncology · Dallas, TXNPI 1487864864
Payments from drug & device makers
Across 1,039 payments — averaging $2773.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1.7M
- Pfizer$401K
- Boehringer Ingelheim$156K
- Roche Products Limited$114K
- AstraZeneca$111K
- Epizyme, Inc.$104K
- plus $319K from 14 others
What the payments were for
- Food & beverage$65100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 657 | $1,676,494 |
| Pfizer | 22 | $400,943 |
| Boehringer Ingelheim | 60 | $155,691 |
| Roche Products Limited | 113 | $114,410 |
| AstraZeneca | 9 | $111,400 |
| Epizyme, Inc. | 65 | $104,452 |
| Mirati Therapeutics, Inc. | 1 | $95,885 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $82,136 |
| Merck | 3 | $32,337 |
| EMD Serono, Inc. | 18 | $30,602 |
| Hoffmann-la Roche Limited | 19 | $29,115 |
| Acerta Pharma LLC | 2 | $25,660 |
| Amgen | 6 | $9,150 |
| Genentech, Inc. | 2 | $9,100 |
| Daiichi Sankyo Inc. | 51 | $3,688 |
| Incyte Corporation | 1 | $1,000 |
| Boehringer Ingelheim Espana S.A. | 1 | $40 |
| Astellas Pharma US Inc | 1 | $19 |
| Morphosys, US Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,882,152 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Dallas
- Sawsan RashdanDallas$29.9M
- David GerberDallas$22.8M
- Joyce O'ShaughnessyDallas$20.8M
- Moshe LevyDallas$19.7M
- Minal BarveDallas$16.7M
- Andrew PaulsonDallas$11.5M
- Hans HammersDallas$11.4M
- James StraussDallas$9.1M
- Larry AndersonDallas$8.7M
- Heather McArthurDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.